Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma

Drug (Brand/Generic)

Cabometyx / cabozantinib

Therapy Class

Tyrosine kinase Inhibitor

Current Indication

Renal cell carcinoma

Market Sector

Oncology

Development Status

Approved in the US and Europe

Developer

Exelixis
Expand

Go Top